Imlifidase Utilization in Glanzmann Thrombasthenia With Anti‐GPIIb/IIIa and Anti‐HLA Alloimmunization and Severe Platelet Refractoriness Following Hematopoietic Stem Cell Transplant
Year: 2024
Type: article
Study design: Case Report
Abstract: Glanzmann Thrombasthenia (GT) is an inherited bleeding disorder of poor platelet function secondary to a defect in platelet membrane glycoprotein IIb/IIIa (GPIIb/IIIa). Patients with GT may develop anti-platelet antibodies including anti-GPIIb/IIIa which can lead to severe refractory thrombocytopenia and life-threatening bleeding, management of which is challenging. We report successful use of imlifidase, a novel IgG protease enzyme, as part of a multimodal approach for management of severe platelet refractoriness and alloimmunization in a child with GT and primary graft failure following hematopoietic stem cell transplant (HSCT). The patient had no detectable anti-platelet alloantibodies following imlifidase, and underwent a second HSCT.
Source: Pediatric Blood & Cancer
DOI: 10.1002/pbc.31412
Authors: Mohammad AlNajjar, Ryan Rochat, Amanda B. Grimes, Amir Navaei, Todd Eagar, Caridad Martinez, Khalid Yassine, Robert Krance, Saleh Bhar
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4404120284